PFG Advisors lowered its holdings in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 1.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 7,844 shares of the medical instruments supplier’s stock after selling 93 shares during the quarter. PFG Advisors’ holdings in Becton, Dickinson and were worth $2,087,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Accel Wealth Management grew its stake in Becton, Dickinson and by 100.0% during the 4th quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 50 shares during the last quarter. Sierra Capital LLC grew its stake in Becton, Dickinson and by 88.7% during the 4th quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. Level Financial Advisors Inc. purchased a new position in Becton, Dickinson and during the 4th quarter worth approximately $26,000. Icapital Wealth LLC purchased a new position in Becton, Dickinson and during the 1st quarter worth approximately $31,000. Finally, Rosenberg Matthew Hamilton grew its stake in Becton, Dickinson and by 61.5% during the 1st quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 48 shares during the last quarter. Institutional investors and hedge funds own 86.58% of the company’s stock.
A number of research analysts recently issued reports on BDX shares. StockNews.com upgraded Becton, Dickinson from a “hold” rating to a “buy” rating in a research note on Friday, June 24th. Piper Sandler dropped their price target on Becton, Dickinson from $265.00 to $255.00 in a research note on Thursday, May 5th. Morgan Stanley increased their price objective on Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research report on Monday, April 11th. Wells Fargo & Company raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective for the company in a research report on Friday, June 24th. Finally, Bank of America assumed coverage on Becton, Dickinson and in a research report on Tuesday, March 1st. They set a “neutral” rating for the company. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $279.17.
In related news, VP Thomas J. Spoerel sold 443 shares of Becton, Dickinson and stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total transaction of $115,180.00. Following the completion of the transaction, the vice president now directly owns 1,058 shares of the company’s stock, valued at $275,080. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Friday, May 6th. The stock was sold at an average price of $256.00, for a total value of $121,600.00. Following the transaction, the executive vice president now directly owns 3,806 shares of the company’s stock, valued at $974,336. The disclosure for this sale can be found here. 0.50% of the stock is owned by company insiders.
BDX opened at $244.53 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The business has a 50-day simple moving average of $250.59 and a 200-day simple moving average of $258.29. The stock has a market capitalization of $69.71 billion, a P/E ratio of 38.57, a P/E/G ratio of 3.39 and a beta of 0.64. Becton, Dickinson and Company has a 12 month low of $231.46 and a 12 month high of $280.62.
Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating the consensus estimate of $2.98 by $0.20. The business had revenue of $5.01 billion during the quarter, compared to analysts’ expectations of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $3.19 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 11.2 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be issued a $0.87 dividend. The ex-dividend date of this dividend is Wednesday, June 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.42%. Becton, Dickinson and’s dividend payout ratio is currently 54.89%.
About Becton, Dickinson and: (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extension sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
See Also:
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).
Receive News & Ratings for Becton Dickinson and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and related companies with MarketBeat.com’s FREE daily email newsletter.
.